Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin's Clinical Research Center for Cancer, Tianjin, 300070, ChinaShandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, 250117, China
刊名
Chinese Journal of Radiological Medicine and Protection
年份
2021
卷号
Vol.41 No.10
页码
790
ISSN
0254-5098
摘要
The role of postoperative adjuvant therapy is crucial for breast cancer. Also, there is no doubt that the combination of effective postoperative radiotherapy and adjuvant systemic therapy can not only reduce the local recurrence rate, but also improve the survival rate of patients. Although the timing of postoperative radiotherapy and part of systemic therapy is clear, some part of treatment regimens still remain elusive. In particular, the safety of concurrent therapy of postoperative consolida...更多
The role of postoperative adjuvant therapy is crucial for breast cancer. Also, there is no doubt that the combination of effective postoperative radiotherapy and adjuvant systemic therapy can not only reduce the local recurrence rate, but also improve the survival rate of patients. Although the timing of postoperative radiotherapy and part of systemic therapy is clear, some part of treatment regimens still remain elusive. In particular, the safety of concurrent therapy of postoperative consolidation chemotherapy and postoperative radiotherapy in patients with neoadjuvant chemotherapy, the safety of concurrent therapy of postoperative dual-targeted therapy and postoperative radiotherapy in HER2-positive patients, and the safety of simultaneous radiotherapy of small molecule inhibitors need to be further clarified. This article reviews the related papers on the sequence selection of postoperative radiotherapy and postoperative adjuvant systemic therapy for breast cancer.收起
